Chinese biotech firm BeiGene closed its trading debut in Hong Kong down 1 % . The underwhelming secondary floatation , which came after strict listing rules , came despite eight investors buying 31 % of the international shares market . BioGene was the second biotech firm to float its stock in Hong Kong and the poor performance is likely to have a negative impact on the other six that have filed for a listing , as the market suffers due to the ongoing US - China trade war . BioGene investor ben Liang said it was " satisfied " with the debut .
Chinese biotech firm BeiGene closed its trading debut in Hong Kong down 1%. The underwhelming secondary floatation, which came after revised listing rules, came despite eight investors buying 31% of the international shares offered. BioGene was the second biotech company to float its stock in Hong Kong and the poor performance is likely to have a negative impact on the other six that have filed for a listing, as the market suffers due to the ongoing US-China trade war. BioGene CFO Howard Liang said it was "satisfied" with the debut.